Project Grant R01DA064144
Award Date 9/30/25
Completion Date 5/31/30
Dollars Obligated $732K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Kentucky, USA
Similar Awards
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will provide $2,331,737 to the University of California, San Francisco (UCSF) to conduct research on the impact of methamphetamine use on immune dysfunction and HIV reservoir transcription among people with HIV receiving antiretroviral therapy. The research will utilize in vivo imaging and post-mortem studies to examine how methamphetamine use...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $962,517 Cooperative Agreement under the Drug Use and Addiction Research Programs (CFDA 93.279) to Public Health Foundation Enterprises, Inc. (Heluna Health) to conduct a two-phase study on the use of the GLP-1 agonist semaglutide for treating methamphetamine use disorder (MEUD). The first phase will be an open-label, single-arm Phase IIA trial to evaluate the eligibility, adherence, and...
- This federal Project Grant award of $457,701 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to understand the pharmacodynamics of combined methamphetamine and fentanyl use. The primary objectives are to: 1) elucidate the mechanisms underlying polysubstance use disorders involving stimulants and opioids, and 2) investigate the role of the hypocretin/orexin neuropeptide system as a potential target for...
- The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded Myosin Therapeutics Inc. a $2,916,991 Project Grant on April 1, 2025 to support a first-in-human double-blind, placebo-controlled single ascending dose (SAD) Phase 1B clinical trial of their novel therapeutic agent MT-110 for reducing methamphetamine use disorder (MUD). With an estimated 4 million people in the U.S. affected by MUD and limited treatment options available, the...
- This federal Project Grant, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $804,728 to the Regents of the University of California at Riverside to investigate the role of the cysteinyl leukotriene-cysteinyl leukotriene receptor 1 (CYSLT-CYSLTR1) axis in promoting HIV-1 persistence and brain injury in individuals living with HIV who use methamphetamine. The 5-year project, starting June 1, 2025, aims to determine...
- This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $552,629 to Temple University to characterize the effects of chemokine receptor antagonists (CRAs) in preclinical models of methamphetamine use disorder (MUD). The 5-year project aims to evaluate whether selectively targeting a trio of chemokine receptors (CXCR4, CCR2, and CCR5) can reduce methamphetamine intake, reinforce efficacy, and...
- This federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) supports research to advance troriluzole as a potential treatment for methamphetamine use disorder (MUD), including for individuals with co-occurring MUD and opioid use disorder. The $634,048 grant, awarded on April 15, 2025, will fund a human laboratory study at the University of Kentucky Research Foundation to evaluate troriluzole's effects in people with MUD...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $3,287,052 Cooperative Agreement (CFDA 93.279 - Drug Use and Addiction Research Programs) to Virogenomics Biodevelopment, Inc., a woman-owned small business in Tigard, Oregon. The award, granted in May 2025, is funding IND-enabling studies and Phase I clinical trials to advance DRHQ, a novel immunotherapeutic compound developed by Virogenomics to treat methamphetamine use disorder. The research...
- The University of California, San Francisco (UCSF) was awarded a $206,180 Project Grant from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) to investigate the complex intersection of HIV, methamphetamine use, and immune dysfunction. The 5-year grant, awarded on Sep 1, 2025, will support a comprehensive, data-driven research approach to examine how methamphetamine exposure influences HIV reservoir transcription and host immune responses, with the...
- This Project Grant award of $198,854 was provided by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant supports a study to measure social isolation, loneliness, and stigma experienced by older adults living with HIV who use methamphetamine. The research will characterize trajectories of social isolation and loneliness over 12 months, and explore patient perspectives on how...